1. Market Research
  2. > Pharmaceutical Market Trends
Global G-Protein Coupled Receptors (GPCRs) Industry

Global G-Protein Coupled Receptors (GPCRs) Industry

  • April 2021
  • 359 pages
  • ID: 5817993
  • Format: PDF
  • Global Industry Analysts

Summary

Table of Contents

MARKET IMPACT SURVEY - COVID-19 & LOOMING RECESSION

Timely market intelligence is paramount in these uncertain times!

We launched an impact survey to update this project with timely insights during 2020. Update frequency will depend upon evolving market conditions and executive opinions. Our participants are executives driving strategy, marketing, sales and product management at competitive companies worldwide. All updates during the rest of the year are complimentary to clients!

Abstract:
- A Lesson Taught by the Pandemic is the Need to Have Better Health Systems & More Effective Drugs. GPCRs to Reach $3.8 Billion On the Back of Increased Drug R&D Spending
- The global market for G-Protein Coupled Receptors (GPCRs) is projected to reach US$3.8 billion by the year 2027, trailing a post COVID-19 CAGR of 5.7% over the analysis period 2020 through 2027. Global healthcare systems continue to be inadequate, leaving a lot to be desired. Over 50% of the world’s population lacks access to essential health services. Low quality healthcare is increasing the burden of disease, morality in addition to pushing up medical costs. COVID-19 is bringing transformational change in the way the world is beginning to prioritize healthcare and drug development. Post pandemic, there will be robust need and demand for the development of new and affordable medicines. The scenario brings good news for G-Protein Coupled Receptors (GPCRs), given the fact that over 45% of all drugs work by targeting GPCRs. The most intensively studied class of drug targets, GPCRs represent signal-transducing molecules that transmit signals to cells. They play a key role in converting extracellular stimulus into intracellular responses, and are therefore responsible for all physiological processes. Also referred to as heptahelical receptor or seven-trans membrane receptor, GPCRs consist of a large family of trans-membrane receptor proteins that play a vital role in signal transduction pathways in various physiological processes. Thus, by targeting GPCRs, a number of cellular functions can be controlled. GPCR-based drugs represent around 40% of the total approved drugs available in the market.
- In addition, GPCRs that were previously untargeted are fast becoming validated targets, with an average of 3.5 receptors each year. G protein-coupled receptors (GPCRs) are membrane proteins that are located on the surface of a cell. Human genome comprises of around 30,000 genes, of which around 10% (3,000) genes are found to be drug gable targets. Out of the 3,000 genes, GPCRs are encoded by approximately 800-1,000 genes in the human body, and thus, comprise of the largest cell-surface receptor family. Furthermore, in the GPCR superfamily only around 360 receptors are non-chemosensory/ non-sensory and thus, are identified as validated drug targets, while the remaining are sensory receptors. GPCRs are present only in eukaryotes such as choanoflagellates and yeast, as well as in animals. GPCRs are also called 7TM receptors, 7trans-membrane domain receptors, serpentine receptors, and G-protein linked receptors (GPLR), and heptahelical receptors. The transmembrane domains are linked by 3 extracellular and 3 intracellular loops. The most important feature of GPCRs is that they are expressed at the surface of the cell, and communicate certain specific aspects of the extra-cellular environment to the intra-cellular environment.
- Drugs targeting GPCR have superior therapeutic benefits, as they are more active at cell surface receptors. The importance of GPCRs can be put into perspective by the fact that approximately 35% to 40% of all pharmaceutical drugs in the marketplace target G-protein coupled receptors, making it one of the most vital classes of proteins in the genome. G protein?coupled receptors (GPCRs) are important drug targets with about 35% of FDA approved drugs targeting these receptors. GPCRs stimulate cellular responses and signal transduction inside the cell, upon sensing molecules outside. GPCR respond to various agonists, including proteins, neurotransmitters, hormones, amines, and photon. Some of the agonists attach themselves to receptor’s extra cellular loop, while others penetrate in the trans-membrane region. Upon activation, a conformational change is induced in the receptor, which in turn activates GPCRs and subsequently biochemical signals are transmitted in the cell. Over the past two decades, there has been much research on understanding working of the receptors at the molecular level. There are also many studies ongoing for developing structure based GPCR drug designing, based on discoveries that various ligands are able to bind to same receptor but stimulate association of other effector proteins to varying extents. Such concept of biased agonism as well as functional selectivity have opened up major possibilities for development of more effective drugs with more desired therapeutic impacts, all while preventing harmful side-effects. Already, there have been many illustrations of how such biased GPCR ligands could prove to be useful in treating various diseases. Nonetheless, there is still much to be learnt about the various mechanisms that govern functional selectivity and ligand bias. Growth is forecast to be primarily driven by the increasing interest in GPCR drug targets, superior understanding of GPCR membrane structures, identification, and crystallization of newer structures, development of more powerful and efficient GPCR screening tools and technologies, and successful extrapolation of known structural information to other GPCRs of therapeutic interest. More than 360 endoGPCRs represent the largest and most therapeutically targeted class of membrane receptors in humans. However only 30-40% that have well-defined biological ligands are drug gable at present. The remaining 60-70% hold significant potential for development of new drug therapeutics.

- Select Competitors (Total 52 Featured) -
  • Abcam plc
  • Addex Pharmaceuticals Ltd.
  • Arena Pharmaceuticals Inc.
  • Becton-Dickinson and Company
  • Eurofins DiscoverX Corporation
  • HD Biosciences Co., Ltd
  • Merck KGaA
  • Perkin Elmer Inc
  • Promega Corporation
  • QIAGEN N.V.
  • Thermo Fisher Scientific, Inc.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2021

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on